Other languages Legend Biotech Corporation

Equities

LEGN

US52490G1022

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
45.3 ^USD	+1.98%		-1.93%	-24.71%

04-23	Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission	MT
04-22	Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma	04-22
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval	04-08
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	04-08
Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma	04-08
U.S. FDA approves expanded use of J&J's cancer cell therapy	04-05
Legend Biotech Corporation's CARVYKTI Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma	04-05
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer	04-05
U.S. FDA allows expanded use of Bristol Myers' cell therapy	04-05
Legend Biotech Files Mixed-Securities Shelf Registration	03-19
Genscript Biotech's US Unit Secures FDA Nod for Anti-Cancer Medication	03-19
Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma	03-15
US FDA panel unanimously backs expanded use of J&J's CAR-T therapy	03-15
US FDA staff flag safety concerns from J&J, Bristol's CAR-T therapies	03-13
Sector Update: Health Care Stocks Lean Lower Premarket Monday	03-11
Legend Biotech Corporation Announces Management Changes	03-11
Legend Biotech Q4 Loss Narrows, Revenue Rises	03-11
CPI, Tech Outlooks Cap Wall Street Pre-Bell; Asia, Europe Off	03-11
Futures Down Pre-Bell Ahead of Key Inflation Data; Asia Churns, Europe Falls	03-11
Legend Biotech Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-11
Legend Biotech Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Legend Biotech Corporation

Equities

LEGN

US52490G1022

Other languages

Filters